Document Detail


Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.
MedLine Citation:
PMID:  18091749     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The blood pressure (BP) of an individual varies considerably from day to day. Hypertension is commonly identified based on the average of two BPs taken at each of two visits, a practice consistent with current guidelines. We hypothesized that (i) in the setting of high-normal BP ("prehypertension"), this practice results in frequent spurious detection of hypertension, and (ii) that random, spurious detection of hypertension and flawed study design together explain why in the Trial of Preventing Hypertension (TROPHY) study candesartan appeared to suppress the development of hypertension for 2 years after cessation of therapy.
METHODS: We used Monte Carlo simulation to quantify spurious detection of hypertension at repeated clinic visits in one million subjects with unchanging usual systolic BPs (SBPs) between 130 and 139 mm Hg and normal BP variability. Criteria for identifying hypertension derived from Rosner and Polk, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), and the Trials of Hypertension Prevention (TOHP), TROPHY, and Framingham studies were applied to Canadian Heart Health Survey data. On the basis of these simulations, we created a three-parameter model of Kaplan-Meier curves recorded in the TROPHY study. We used the model to analyze the rates at which hypertension was identified in the TROPHY study.
RESULTS: TROPHY criteria spuriously identify hypertension in 76% of subjects over 18 clinic visits. Higher rates of spurious detection of hypertension are seen with JNC 7, TOHP and Framingham study criteria. Even highly conservative criteria falsely identify hypertension in 27% of subjects over 18 visits. Our three-parameter model suggests no postdiscontinuation benefit of candesartan.
CONCLUSIONS: When applied over multiple visits, current criteria for detecting hypertension are intolerant of normal BP variation. The use of conservative criteria would reduce spurious identification of hypertension. The apparent long-term beneficial effect of candesartan seen in the TROPHY study can be explained by an inadequate method for detecting hypertension, and flawed study design.
Authors:
Martin J Turner; Johan M van Schalkwyk
Related Documents :
6375339 - Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide.
19461649 - Obstructive sleep apnea syndrome and hypertension: mechanism of the linkage and 24-h bl...
17293739 - Prehypertension as a risk factor for cardiovascular diseases.
10574419 - The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide ...
20198199 - Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients.
16121199 - Factors associated with hypertension awareness, treatment, and control in ghana, west a...
24526559 - A comparative analysis of leukocyte and leukocyte subtype counts among isolated systoli...
8748769 - Clinical experience with a new pressure-adjustable shunt valve.
8610609 - Impact of ambulatory blood pressure on left ventricular diastolic dysfunction in uncomp...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hypertension     Volume:  21     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-19     Completed Date:  2008-03-13     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  85-91     Citation Subset:  IM    
Affiliation:
Department of Anaesthesia, University of Sydney, New South Wales, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Antihypertensive Agents / administration & dosage*
Benzimidazoles / administration & dosage*
Blood Pressure / drug effects*
Computer Simulation*
Diagnostic Errors / prevention & control
Drug Administration Schedule
Humans
Hypertension / diagnosis,  drug therapy*,  epidemiology,  physiopathology
Incidence
Models, Cardiovascular
Monte Carlo Method
Randomized Controlled Trials as Topic
Reproducibility of Results
Research Design
Systole
Tetrazoles / administration & dosage*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Tetrazoles; S8Q36MD2XX/candesartan
Comments/Corrections
Comment In:
Am J Hypertens. 2008 Jan;21(1):3-4   [PMID:  18091733 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Calcium channel blockers suppress cytokine-induced activation of human neutrophils.
Next Document:  Impaired diurnal blood pressure variation and all-cause mortality.